Mo Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mo Chen has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Liwei Duan
Department of Endoscopy, The Second Hospital of Jilin University, Changchun, China
1 shared publication - Peng Gao
Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Jilin University
1 shared publication - Tong Xin
Department of Respiratory, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China
1 shared publication - Yanling Xu
Department of Geriatrics and General Medicine, the Second Hospital of Jilin University, Changchun, Jilin, China
1 shared publication
Latest Publications
- Open Access
- 25 June 2018
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 124
Interleukin-32: its role in asthma and potential as a therapeutic agent
Interleukin (IL)-32, also named natural killer cell transcript 4 (NK4), has increasingly been described as an immunoregulator that controls cell differentiation and cell death and is involved in the stimulation of anti−/pro-inflammatory cytokines. Abnormal presence of IL-32 has been repeatedly noticed during the pathogenesis of allergic, infectious, cancerous, and inflammatory diseases. Of particular note was the observation of the anti-inflammatory property of IL-32 in a murine ovalbumin model of allergic asthma. Compared to wild-type mice, IL-32γ transgenic mice show decreased levels of inflammatory cells, recruited eosinophils, and lymphocytes in bronchoalveolar lavage fluid in a mouse model of acute asthma. To date, the molecular mechanism underlying the role of IL-32 in asthma remains to be elucidated. This review aims to summarize recent advances in the pathophysiology of asthma and describe the links to IL-32. The possibilities of using IL-32 as an airway inflammation biomarker and an asthma therapeutic agent are also evaluated.
- 25 June 2018
- Published by Springer Nature in Respiratory Research
- Vol. 19 (1) , 124
Open AccessInterleukin-32: its role in asthma and potential as a therapeutic agent
Interleukin (IL)-32, also named natural killer cell transcript 4 (NK4), has increasingly been described as an immunoregulator that controls cell differentiation and cell death and is involved in the stimulation of anti−/pro-inflammatory cytokines. Abnormal presence of IL-32 has been repeatedly noticed during the pathogenesis of allergic, infectious, cancerous, and inflammatory diseases. Of particular note was the observation of the anti-inflammatory property of IL-32 in a murine ovalbumin model of allergic asthma. Compared to wild-type mice, IL-32γ transgenic mice show decreased levels of inflammatory cells, recruited eosinophils, and lymphocytes in bronchoalveolar lavage fluid in a mouse model of acute asthma. To date, the molecular mechanism underlying the role of IL-32 in asthma remains to be elucidated. This review aims to summarize recent advances in the pathophysiology of asthma and describe the links to IL-32. The possibilities of using IL-32 as an airway inflammation biomarker and an asthma therapeutic agent are also evaluated.